Literature DB >> 9249047

1.8-A crystal structure of the catalytic domain of human neutrophil collagenase (matrix metalloproteinase-8) complexed with a peptidomimetic hydroxamate primed-side inhibitor with a distinct selectivity profile.

M Betz1, P Huxley, S J Davies, Y Mushtaq, M Pieper, H Tschesche, W Bode, F X Gomis-Rüth.   

Abstract

Matrix metalloproteinases (MMP) are zinc endopeptidases involved in tissue remodelling. They have been implicated in a series of pathologies, including cancer, arthritis, joint destruction and Alzheimer's disease. Human neutrophil collagenase represents one of the three interstitial collagenases that cleave triple-helical collagen of type I, II and III. Its catalytic domain (residues Phe79-Gly242) has been heterologously expressed in Escherichia coli and crystallized as a non-covalent complex with the hydroxamate inhibitor BB-1909, which has distinct selectivity against different MMP, in a crystal form. The crystal structure, refined to 0.18-nm resolution, shows that BB-1909 is a right-hand-side inhibitor that binds to the S1'-S3' subsites and coordinates to the catalytic Zn2+ in a bidentate manner via the hydroxyl and carbonyl oxygen atoms of the hydroxamate group in a similar manner to batimastat. The collagenase/BB-1909 complex is described in detail and compared with the collagenase/batimastat complex. These studies provide information on MMP specificity and thus may assist the development of more-selective MMP inhibitors.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9249047     DOI: 10.1111/j.1432-1033.1997.00356.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  9 in total

Review 1.  Matrix metalloproteinase inhibitors.

Authors:  Nithya Ramnath; Patrick J Creaven
Journal:  Curr Oncol Rep       Date:  2004-03       Impact factor: 5.075

2.  Structural basis for matrix metalloproteinase-2 (MMP-2)-selective inhibitory action of β-amyloid precursor protein-derived inhibitor.

Authors:  Hiroshi Hashimoto; Tomoka Takeuchi; Kyoko Komatsu; Kaoru Miyazaki; Mamoru Sato; Shouichi Higashi
Journal:  J Biol Chem       Date:  2011-08-03       Impact factor: 5.157

3.  The structure of the catalytic domain of Tannerella forsythia karilysin reveals it is a bacterial xenologue of animal matrix metalloproteinases.

Authors:  Núria Cerdà-Costa; Tibisay Guevara; Abdulkarim Y Karim; Miroslaw Ksiazek; Ky-Anh Nguyen; Joan L Arolas; Jan Potempa; F Xavier Gomis-Rüth
Journal:  Mol Microbiol       Date:  2010-11-02       Impact factor: 3.501

Review 4.  Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer.

Authors:  Roopali Roy; Jiang Yang; Marsha A Moses
Journal:  J Clin Oncol       Date:  2009-09-08       Impact factor: 44.544

5.  Computational insights into the selectivity mechanism of APP-IP over matrix metalloproteinases.

Authors:  Lingling Geng; Jian Gao; Wei Cui; Yancheng Tang; Mingjuan Ji; Bozhen Chen
Journal:  J Comput Aided Mol Des       Date:  2012-12-09       Impact factor: 3.686

Review 6.  Structural aspects of the metzincin clan of metalloendopeptidases.

Authors:  F Xavier Gomis-Rüth
Journal:  Mol Biotechnol       Date:  2003-06       Impact factor: 2.695

7.  Molecular design of a highly selective and strong protein inhibitor against matrix metalloproteinase-2 (MMP-2).

Authors:  Shouichi Higashi; Tomokazu Hirose; Tomoka Takeuchi; Kaoru Miyazaki
Journal:  J Biol Chem       Date:  2013-02-10       Impact factor: 5.157

8.  Computational study of the catalytic domain of human neutrophil collagenase. specific role of the S3 and S'3 subsites in the interaction with a phosphonate inhibitor.

Authors:  Massimiliano Aschi; Danilo Roccatano; Alfredo Di Nola; Carlo Gallina; Enrico Gavuzzo; Giorgio Pochetti; Michael Pieper; Harald Tschesche; Fernando Mazza
Journal:  J Comput Aided Mol Des       Date:  2002-03       Impact factor: 3.686

9.  Targeting angiogenesis for treatment of human cancer.

Authors:  R R Somani; U V Bhanushali
Journal:  Indian J Pharm Sci       Date:  2013-01       Impact factor: 0.975

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.